June 11, 2025 8-Week Oral Therapy Approved for Acute HCV The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention. Conexiant
June 20, 2025 Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer The ASCO Post
June 20, 2025 Symptom-Detected Breast Cancers May Be Linked to Higher Mortality and Advanced Disease Risk The ASCO Post
June 20, 2025 How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival The ASCO Post
June 16, 2025 Vepdegestrant Improves Progression-Free Survival in Select Patients With ESR1-Mutant Advanced Breast Cancer The ASCO Post
June 16, 2025 Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer The ASCO Post
June 19, 2025 Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds The ASCO Post
June 19, 2025 Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds The ASCO Post
June 17, 2025 Proposed Budget Cuts to Medicaid May Result in More Than 16,500 Medically Preventable Deaths Annually The ASCO Post
June 17, 2025 I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World The ASCO Post
June 02, 2025 Industry Insights: Mark L. Baum, Founder and Chief Executive Officer, Harrow Optometric Management